In This Article:
HUTCHMED (China) (LON:HCM) Full Year 2024 Results
Key Financial Results
-
Revenue: US$630.2m (down 25% from FY 2023).
-
Net income: US$37.7m (down 63% from FY 2023).
-
Profit margin: 6.0% (down from 12% in FY 2023). The decrease in margin was driven by lower revenue.
-
EPS: US$0.044 (down from US$0.12 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
HUTCHMED (China) EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) exceeded analyst estimates.
Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are up 3.4% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for HUTCHMED (China) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.